Home » Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland

Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland - TriNetX

Contact Us
Submit RFI/RFP
Trust Center
Ethics Hotline (report a violation)

LIFE SCIENCES
HEALTHCARE
RESOURCES
ABOUT
SIGN IN
- TriNetX LIVE™
- EVIDEX®

Trial Design
Datasets & Analytics
Non-US Oncology
RWE Generation
Drug Safety

Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland

Jul 20, 2023

View

Search for:

SOLUTIONS

Clinical Trial Design & Optimization

Data Sets & Analytics

Non-US Oncology

Insights & Evidence Generation

Drug Safety & Pharmacovigilance

WHO WE SERVE

Healthcare Organizations

RESOURCES

Explore TriNetX RWD

ENTERPRISE

Board of Directors

EMAIL OPT-IN

Get the latest on product updates, services, events, expert insights, and top industry trends.

ABOUT TRINETX, LLC

TriNetX operates the world’s broadest federated network of real-world data in partnership with healthcare providers and applies intelligence that accelerates innovation across the healthcare ecosystem. Through its self-service, HIPAA-, GDPR-, and LGPD-compliant platform of federated deidentified and anonymous electronic health record datasets and consulting partnerships, TriNetX empowers its global community to improve clinical trial protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation.

TriNetX, LLC complies with all applicable privacy laws. For more information please visit our Trust Center.

FOLLOW US

LinkedIn

© TriNetX, LLC All Rights Reserved.

Privacy & Cookies

Do not sell or share my personal information